- Home
- CHI vs DNA Comparison
CHI vs DNA Comparison
Compare CHI & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- DNA
- Stock Information
- Founded
- CHI 2002
- DNA 2008
- Country
- CHI United States
- DNA United States
- Employees
- CHI N/A
- DNA N/A
- Industry
- CHI Investment Managers
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHI Finance
- DNA Health Care
- Exchange
- CHI Nasdaq
- DNA Nasdaq
- Market Cap
- CHI 820.8M
- DNA 731.1M
- IPO Year
- CHI N/A
- DNA N/A
- Fundamental
- Price
- CHI $10.64
- DNA $10.08
- Analyst Decision
- CHI
- DNA Hold
- Analyst Count
- CHI 0
- DNA 2
- Target Price
- CHI N/A
- DNA $9.50
- AVG Volume (30 Days)
- CHI 186.2K
- DNA 1.6M
- Earning Date
- CHI 01-01-0001
- DNA 11-11-2025
- Dividend Yield
- CHI 9.90%
- DNA N/A
- EPS Growth
- CHI N/A
- DNA N/A
- EPS
- CHI N/A
- DNA N/A
- Revenue
- CHI N/A
- DNA $230,815,000.00
- Revenue This Year
- CHI N/A
- DNA N/A
- Revenue Next Year
- CHI N/A
- DNA $13.73
- P/E Ratio
- CHI N/A
- DNA N/A
- Revenue Growth
- CHI N/A
- DNA 25.21
- 52 Week Low
- CHI $9.70
- DNA $5.00
- 52 Week High
- CHI $11.61
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- CHI 67.50
- DNA 38.96
- Support Level
- CHI $10.28
- DNA $10.11
- Resistance Level
- CHI $10.44
- DNA $11.97
- Average True Range (ATR)
- CHI 0.08
- DNA 0.80
- MACD
- CHI 0.03
- DNA -0.23
- Stochastic Oscillator
- CHI 89.74
- DNA 4.77
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.